Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This systematic review details monitoring and safety guidelines for primary care physicians regarding Janus kinase and tyrosine kinase 2 inhibitors used in treating inflammatory skin conditions, emphasizing their efficacy and the importance of updated knowledge due to associated box warnings and increasing use.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

CTP-543 is generally safe for treating alopecia areata.

Deuruxolitinib is generally safe for treating alopecia areata.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study presents the first documented case of dramatic hair regrowth in a systemic lupus erythematosus patient with refractory alopecia following tofacitinib therapy, suggesting a potential new application for JAK inhibitors in difficult-to-treat cutaneous SLE manifestations.

This study suggests that interleukin-15 plays a complex role in alopecia areata, potentially contributing to immune infiltration while also protecting against hair follicle immune privilege collapse and promoting hair growth.

This review explores animal models of alopecia areata, particularly focusing on the insights they've provided into the disease's immune mechanisms and potential treatment approaches, without reporting new experimental data.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This study found that in a tertiary academic institution, nearly 1 in 5 dermatology consults were for drug-related skin reactions, with antibiotics frequently identified as the culprits.

This source discusses that while oral JAK inhibitors are used for treating lichen planopilaris and frontal fibrosing alopecia, they carry significant risk of adverse events; two cases showed promising results using tofacitinib cream as a safer topical alternative.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

This study found that tofacitinib was safe and effective for patients with severe or treatment-resistant alopecia areata, alopecia totalis, and alopecia universalis, resulting in significant hair regrowth for most participants.

This article reports a case of rapidly progressive alopecia areata totalis in a COVID-19 patient that did not respond to treatment with tofacitinib; no new clinical results are discussed.

This study reports that tofacitinib, a JAK 1/3 inhibitor, showed significant improvement in a patient with co-occurring severe alopecia totalis and lichen planus hypertrophicus, conditions that are typically resistant to treatment.

This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.

This source reports that based on international Phase 3 trial results, the JAK1/2 inhibitor baricitinib was approved in Japan in June 2022 for treating extensive alopecia areata, offering a potentially useful treatment option.